Congressional Dem Claims Votes Secured for Federal Cannabis Reform
Senior Democratic lawmaker asserts sufficient congressional support exists for federal marijuana legislation, signaling potential breakthrough for stalled reform efforts.
A senior Democratic congressional leader claims federal cannabis reform legislation now has the necessary votes to advance, marking a potential turning point for an industry that has weathered years of regulatory uncertainty. The assertion comes as cannabis companies trade at steep discounts to traditional consumer goods peers, largely due to federal prohibition that restricts banking access and imposes punitive tax burdens.
The timing proves critical for multi-state operators like Curaleaf Holdings, Green Thumb Industries, and Cresco Labs, which have built substantial operations across state-legal markets while operating under the constraints of federal illegality. These companies face effective tax rates exceeding 70% due to Internal Revenue Code Section 280E, which prohibits standard business deductions for federally illegal activities. Federal reform would immediately improve margins and cash flows across the sector.
Cannabis stocks have underperformed broader markets throughout 2026, with the AdvisorShares Pure US Cannabis ETF down approximately 15% year-to-date as investors grew skeptical about reform prospects. However, recent legislative momentum suggests a shift in congressional dynamics, particularly as state-level legalization continues expanding and public support for federal reform reaches new highs in polling data.
The Democratic leadership's confidence reflects growing bipartisan recognition that current federal policy creates untenable contradictions between state and federal law. Over 40 states now permit some form of cannabis use, creating a patchwork regulatory environment that complicates compliance and limits interstate commerce. Federal reform would unlock significant operational efficiencies and capital market access for cannabis operators currently restricted to limited financing options.
While congressional vote counting often proves optimistic, the cannabis industry's institutional investors are positioning for potential policy breakthroughs. Major institutional funds have increased cannabis allocations in recent quarters, anticipating that federal reform could trigger substantial revaluations across the sector. The combination of normalized taxation, banking access, and interstate commerce could fundamentally reshape cannabis company valuations and competitive dynamics.